Acute worsening of glycemic control in a patient with type 2 diabetes
and non-small cell lung cancer after administration of lorlatinib
- Yoshio NAKANO
, - Mai MIYASATO-ISODA,
- Iwao GHOMA,
- Tomomi FUJISAWA
Abstract
A case with non-small cell lung cancer exhibited extreme hyperglycemia
after lorlatinib treatment, whose adverse effects on hyperglycemia is
little known. But, the lorlatinib could be continued by intensifying
diabetes treatment, indicating the importance of glucose monitoring
during lorlatinib administration, and of adequate intensification of
treatment for such hyperglycemia.23 Sep 2021Submitted to Clinical Case Reports 24 Sep 2021Submission Checks Completed
24 Sep 2021Assigned to Editor
30 Sep 2021Reviewer(s) Assigned
19 Oct 2021Review(s) Completed, Editorial Evaluation Pending
20 Oct 2021Editorial Decision: Revise Minor
08 Dec 20211st Revision Received
11 Dec 2021Submission Checks Completed
11 Dec 2021Assigned to Editor
11 Dec 2021Review(s) Completed, Editorial Evaluation Pending
22 Dec 2021Editorial Decision: Accept
